GlyT1 inhibitors for use in the treatment of hematological disorders

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9877963
SERIAL NO

15334722

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is related to compounds, which are GlyT1 inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HOFFMANN-LA ROCHE INC150 CLOVE ROAD OVERLOOK AT GREAT NOTCH SUITE 8 LITTLE FALLS NJ 07424

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Alberati, Daniela Grenzach-Wyhlen, DE 7 71
Koerner, Annette Grenzach-Wyhlen, DE 1 2
Pinard, Emmanuel Linsdorf, FR 113 721
Winter, Michael Freiburg, DE 74 1396

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 30, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 30, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00